Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer

Cisplatin (CDDP)-based combination chemotherapy remains the mainstream treatment for advanced bladder cancer. However, its efficacy is often limited due to the development of resistance for which underlying mechanisms are poorly understood. Meanwhile, emerging evidence has indicated the involvement...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Kashiwagi, Eiji, Ide, Hiroki, Inoue, Satoshi, Kawahara, Takashi, Zheng, Yichun, Reis, Leonardo O., Baras, Alexander S., Miyamoto, Hiroshi
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226499/
https://ncbi.nlm.nih.gov/pubmed/27322140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9994
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars